Former VP at Integer Holdings Corp
- Recent trends and developments within the medical device CDMO (contract development and manufacturing organisation) market, including strengths and weaknesses of Integer (NYSE: ITGR), Cirtec and Velentium
- Assessment of infrastructure to shore up supply chains and mitigate inefficiencies
- Insourcing vs outsourcing trends between large medical technology manufacturers and OEMs delineated by customer size
- Potential margin expansion opportunities and H2 2023 growth outlook
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.